www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Oncology
All latest versions
3 December 2024
4 June 2024
5 December 2023
6 June 2023
7 December 2022
7 June 2022
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by publication date
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
Bladder cancer
Abnobaviscum 900
Durvalumab
IND
Enfortumab vedotin
IND
Erdafitinib
Mitomycine extended release
Nivolumab
Extension of indication to include in combination with cisplatin-based chemotherapy the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
IND
OPDIVO in combination with cisplatin-based chemotherapy is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
IND
Sacituzumab Govitecan
IND
Sasanlimab
Brain cancer
2-hydroxy Oleic Acid
Berubicin
Dordaviprone
Paclitaxel trevatide
Vorasidenib
Breast cancer
Abemaciclib
IND
Atezolizumab
IND
Camizestrant
Camizestrant in combination with CDK4/6 inhibitors for add-on treatment of locoregionally recurrent or metastatic ER-positive, HER2-negative, ESR1-positive Breast cancer in adults and elderly. (SERENA-6)
Camizestrant in combination with palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.
Capivasertib
Datopotamab deruxtecan
Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with inoperable or metastatic HR-Positive, HER2-negative Breast Cancer who have been treated with one or two prior lines of systemic chemotherapy.
IND
Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with locally recurrent inoperable or metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
IND
Elacestrant
Gedatolisib
Gedatolisib in combination with fulvestrant for second line or later treatment of advanced or metastatic PIK3CA wild-type hormone receptor positive HER2 negative breast cancer in adults and elderly previously treated with CDK4/6 and aromatase inhibitor therapy
Gedatolisib in combination with palbociclib and fulvestrant for second line or later treatment of advanced or metastatic PIK3CA mutated Hormone receptor positive HER2 negative breast cancer in adults and elderly previously treated with CDK4/6 and aromatase inhibitor therapy.
Imlunestrant
Inavolisib
Lasofoxifene
Olaparib
IND
Palbociclib
IND
Ribociclib
IND
Sacituzumab govitecan
IND
Trastuzumab deruxtecan
Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens.
Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
IND
Extension of indication to include treatment of HER2-low/ultra-low hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
IND
Vepdegestrant
Cervical cancer
Cadonilimab
Durvalumab
IND
Olaparib
IND
Pembrolizumab
IND
Tisotumab vedotin
Colon cancer
Fruquintinib
Nivolumab
IND
Pembrolizumab / favezelimab
Zanzalintinib
Head and neck cancer
Buparlisib
Cetuximab sarotalocan
Leukocyte interleukin
Tislelizumab
IND
Xevinapant
Kidney cancer
Abexinostat
Belzutifan
Cabozantinib
IND
Nivolumab/hyaluronidase Ph20
IND
Zanzalintinib
Liver cancer
Atezolizumab
IND
Camrelizumab
Durvalumab
Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC.
IND
Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).
IND
Lenvatinib
IND
Namodenoson
Nivolumab
IND
Nofazinlimab
Tremelimumab
Lung cancer
Alectinib
IND
Amivantamab
Amivantamab in combination with carboplatin and pemetrexed for the first‑line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.
IND
Amivantamab in combination with lazertinib is indicated for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
IND
In combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor.
IND
Atezolizumab
Subcutaneous formulation of atezolizumab for treatment of PD-(L)-1 Cancer Immunotherapy in multiple tumor types.
IND
Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy.
IND
Aumolertinib (mesilate)
Cobolimab
Datopotamab deruxtecan
Domvanalimab
Durvalumab
Lokaal gevorderd, niet-resectabel NSCLC (stadium III)
IND
Completely resected NSCLC
IND
Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab.
IND
Extension of indication to include IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements.
IND
Encorafenib
IND
Furmonertinib
Ivonescimab
Lazertinib
Lenvatinib
IND
Lurbinectedin
Ociperlimab
Osimertinib
Extension of indication to include treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum based chemoradiation therapy.
IND
Osimertinib in combination with pemetrexed and platinum based chemotherapy for locally advanced (clinical stage IIIB, IIIC) or metastatic Non-Small Cell Lung Cancer (NSCLC) (clinical stage IVA or IVB) or recurrent Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy.
IND
Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer
IND
Patritumab deruxtecan
IND
Pembrolizumab
IND
Pembrolizumab / vibostolimab
Pembrolizumab/hyaluronidase
IND
Retifanlimab
IND
Sacituzumab Govitecan
IND
Serplulimab
Sugemalimab
Tarlatamab
Tiragolumab
In combination with atezolizumab for first line treatment of locally advanced, unresectable stage III Non-small cell lung cancer in adults and elderly who have no progression during or following concurrent platinum-based chemoradiotherapy.
Tiragolumab in combination with Atezolizumab for first line treatment of locally advanced unresectable or metastatic high PD-L1, EGFR-negative, ALK-negative Non-small cell lung cancer in adults and elderly.
Tislelizumab
Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab
Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous non-small cell lung cancer who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC
Tizveni in combination with pemetrexed and platinum‑containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC
Locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous or non-squamous) who have disease progression during or after a platinum-containing regimen.
IND
Extension of indication to include first-line treatment of adult patients with extensive-stage Small Cell Lung Cancer (SCLC) for Tevimbra in combination with etoposide and platinum chemotherapy
IND
Trastuzumab deruxtecan
IND
Tremelimumab
Neuroendocrine cancer
Cabozantinib
IND
Lutetium (177Lu) edotreotide
Lutetium (177Lu) oxodotreotide
IND
Lutetium (177Lu) zadavotide guraxetan
Mirdametinib
Oncology other
Afamitresgene autoleucel
Belzutifan
Bezuclastinib
Catequentinib
Catumaxomab
Dostarlimab
Extension of indication to include in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability high (MSI H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy
IND
MMRp EC
IND
Durvalumab
IND
Efbemalenograstim alfa
Entrectinib
IND
Ivosidenib
Letetresgene autoleucel
Melphalan hydrochloride
Nirogacestat
Ozekibart
Pembrolizumab
Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma.
IND
Keytruda, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy
IND
Pimicotinib
Repotrectinib
Retifanlimab
Patiënten met inoperabele, lokaal gevorderd of gemetastaseerd plaveiselcarcinoom van het anale kanaal.
ZYNYZ is geïndiceerd als monotherapie voor de eerstelijnsbehandeling bij volwassen patiënten met gemetastaseerd of recidiverend lokaal gevorderd merkelcelcarcinoom (MCC) dat niet vatbaar is voor curatieve chirurgie of bestraling.
Selinexor
IND
Sugemalimab
IND
Tebentafusp
Tislelizumab
IND
Toripalimab
Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.
Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Varegacestat
Vimseltinib
Zanidatamab
Ovarian cancer
Catequentinib
Dostarlimab
IND
Mirvetuximab soravtansine
Olaparib
IND
Pancreatic cancer
Gemcitabine
IND
Glufosfamide
Prostate cancer
177Lu-PNT2002
Aglatimagene besadenovec
Apalutamide
IND
Atezolizumab
IND
Capivasertib
IND
Darolutamide
Nubeqa is indicated for the treatment of adult men with metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy .
IND
Extension of indication to include in combination with androgen deprivation therapy (ADT) the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC)
IND
Lutetium (177lu) vipivotide tetraxetan
Niraparib
IND
Niraparib-abirateron fixed dose combinatie
IND
Olaparib
IND
Radium-223
IND
Relugolix
Rucaparib
IND
Talazoparib
Talzenna is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
IND
Talzenna in combinatie met enzalutamide is geïndiceerd voor de eerstelijnsbehandeling van patiënten met een gemetastaseerd, hormoonsensitief HRR+ prostaatcarcinoom
IND
Skin cancer
Daromun
IO102-IO103
Ipilimumab
IND
Lifileucel
Nemvaleukin alfa
IND
Nivolumab/relatlimab/hyaluronidase Ph20
Relatlimab / nivolumab
Tucidinostat
Stomach cancer
Bemarituzumab
Ripretinib
Tislelizumab
IND
Trastuzumab deruxtecan
IND
Zolbetuximab
Thyroid cancer
Selpercatinib
IND
Tumour agnostic medication
MDM2-p53 antagonist
Selpercatinib
IND
Unknown
Tovorafenib
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
Over de Horizonscan
About the Horizon Scan
Nederlands
English